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Abstract
Background: The availability of new vaccines can prompt policy makers to consider changes to the routine childhood
immunisation programme in the UK. Alterations to one aspect of the schedule may have implications for other areas
of the programme (e.g. adding more injections could reduce uptake of vaccines featuring later in the schedule).
Colleagues at the Department of Health (DH) in the UK therefore wanted to know whether assessing the impact
across the entire programme of a proposed change to the UK schedule could lead to different decisions than
those made on the current case-by-case basis. This work is a first step towards addressing this question.
Methods: A novel framework for estimating the effective coverage against all of the diseases within a vaccination
programme was developed. The framework was applied to the current (August 2015) UK childhood immunisation
programme, plausible extensions to it in the foreseeable future (introducing vaccination against Meningitis B and/or
Hepatitis B) and a “what-if” scenario regarding a Hepatitis B vaccine scare that was developed in close collaboration
with DH.
Results: Our applications of the framework demonstrate that a programme-view of hypothetical changes to the
schedule is important. For example, we show how introducing Hepatitis B vaccination could negatively impact aspects
of the current programme by reducing uptake of vaccines featuring later in the schedule, and illustrate that the
potential benefits of introducing any new vaccine are susceptible to behaviour changes affecting uptake (e.g. a vaccine
scare). We show how it may be useful to consider the potential benefits and scheduling needs of all vaccinations on
the horizon of interest rather than those of an individual vaccine in isolation, e.g. how introducing Meningitis B
vaccination could saturate the early (2-month) visit, thereby potentially restricting scheduling options for Hepatitis B
immunisation should it be introduced to the programme in the future.
Conclusions: Our results demonstrate the potential benefit of considering the programme-wide impact of
changes to an immunisation schedule, and our framework is an important step in the development of a
means for systematically doing so.
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Background
The UK’s routine childhood immunisation programme
aims to protect children against a number of preventable
infectious diseases over the first 5 years of life. At the time
of this work (August 2015), the current programme pro-
tects against 11 different diseases and is scheduled as
shown in Table 1. The schedule has evolved over time and
is expected to further evolve in response to changing
circumstances, such as the availability of new vaccines.
Decisions to change the immunisation programme are
currently made on a case-by-case basis, informed primarily
by cost-effectiveness analysis specific to the vaccine change
being considered [1–5]. Typical changes might involve
introducing a new vaccine to protect against a disease not
previously covered, or changing the vaccine product used
to protect against a disease already in the programme.
However, alterations to one aspect of the schedule,
whether to the timing of existing vaccinations or the
introduction of a new vaccine product, may have implica-
tions for other areas of the programme. For example,
there are potential mechanisms whereby adding more
injections to the schedule could reduce the uptake of
vaccines that feature later in the schedule [6–12]. For
instance, the likelihood that a parent brings their child to
a particular visit may depend on the number of visits they
have already attended (visit fatigue) and/or whether any of
these visits involved a “bad experience”, as well as the
perceived importance and safety of each vaccine scheduled
for that visit. This introduces the scope for changes to the
programme having less overall benefit than anticipated -
or even causing net harm.
Given this, it is important to consider whether asses-
sing the overall programme-level impact of a proposed
change to the schedule could lead to different decisions
than those made on a case-by-case basis. However, at
present, decision-makers do not have a systematic way
to do this. For example, there is no framework for
exploring the impact that a particular change to the
immunisation schedule might have on the coverage
achieved for other diseases that occur later in the
programme and thus the potential consequences on the
overall burden of vaccine preventable disease on the
population. Authors from the UK Department of
Health (DH) (GW and PG) asked the other authors
to explore collaboratively the feasibility of developing
such a framework that could be used for future UK
immunisation planning.
Within the context of the US immunisation schedule,
previous work has considered the optimal formulation
of combination vaccines using integer programming, in-
corporating schedule-relevant constraints and capturing
the associated costs [13–17]. Jacobson et al. [13] devel-
oped a web-based tool that enables decision-makers to
use economic factors beyond vaccine purchase price to
design childhood vaccine formularies within a given
context, including the value of existing and new combin-
ation vaccines. In contrast to this previous work, we do
not consider costs in this paper and instead focus our
study on developing a framework to estimate how changes
to the vaccine programme could impact the effective
coverage against each disease in order to inform decision
making, given the current schedule. With the intent of
Table 1 The current UK childhood vaccination schedule
The current childhood vaccination schedule in the UK by age of the child, showing the diseases covered and the vaccines that can be used (brand names given).
aNote that the introduction of Meningococcal serogroup B (Men B) has been agreed but has not yet started
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illustrating how a programme-view of vaccine procure-
ment could be beneficial, we apply the framework to the
current UK childhood immunisation programme (August
2015) and explore a selection of feasible future changes to
the schedule. The parameter space and set of con-
straints we consider is thus smaller than in Jacobson
et al.’s work. The development and application of our
framework is an important first step towards evaluat-
ing the programme-level impact of changes in a given
childhood immunisation programme.
Methods
A modelling framework for evaluating vaccine schedules
was developed (Fig. 1) in order to estimate the effective
coverage that would be achieved against each disease
included in a given vaccination programme (section
Developing a modelling framework to estimate the ef-
fective coverage against all diseases within a schedule).
To demonstrate the potential use of our approach, we
parametrised (section Inputs for the modelling frame-
work) and applied (section Application of the framework
to different vaccine scenarios) the framework to the
current childhood vaccination programme in the UK
(August 2015) and plausible future extensions to this
vaccination programme. Our modelling approach does not
use a dataset or database but rather draws on parameters
estimated from the literature, expert opinion or vaccine
manufacturer information (as referenced in the text).
Developing a modelling framework to estimate the
effective coverage against all diseases within a schedule
One way in which the introduction of a new vaccine
could impact on the entire schedule is through influen-
cing the uptake of other vaccines. Therefore we devel-
oped a simple method to estimate the effective coverage
that would be achieved for each disease included in a
given vaccination programme among a cohort of
children at each month over the first five years of life.
Effective coverage against a given disease was calculated
as the product of the uptake of the vaccine and the
vaccine efficacy. We used a simple simulation model to
estimate uptake, the key features of which are illustrated
in Fig. 2. Within the simulation framework, parameters
regarding the immunisation schedule, efficacies of the
relevant vaccines and assumptions around vaccine
uptake (section Inputs for the modelling framework) are
used to calculate an estimated vector of effective cover-
age across all diseases for each of the first 60 months of
life. Parameter estimates were based on the literature
and expert advice, and tuned such that the coverage esti-
mated from the simulation is consistent with recent na-
tional data on uptake from the Cover of Vaccination
Evaluated Rapidly (COVER) dataset [18]. We note that
exact fits to COVER data would not be expected since
COVER is a cross-sectional dataset and the simulation is
a longitudinal cohort model. COVER data was only used
to check that our assumptions regarding age-dependent
attendance and bad experiences led to plausible
estimates of uptake at 1 year, 2 years and 5 years. All
parameter estimates were agreed with the Department
of Health (DH) in the UK and can be changed by the
user (see below for details).
Assumptions regarding vaccine uptake
Within the model, we assume that every child is eligible
for each vaccine (i.e. contra-indications are ignored).
Several studies have reported that parent attitudes
towards vaccination vary by disease and they are less
likely to vaccinate their children against diseases that are
not perceived as a threat, whilst a small percentage of
parents may ‘opt out’ of vaccination entirely (1.1 % [12]).
In the model we therefore incorporated a percentage of
‘non-participants’ for each of the vaccines, and split the
vaccines into three groups defined by their relative
Fig. 1 A schematic of the modelling framework developed in this paper. Using inputs on the effectiveness of vaccines and vaccine uptake, the
framework estimates the age-dependent effective coverage against each of the diseases, calculated as the product of vaccine uptake and
vaccine efficacy
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likelihood of refusal (Table 2). We also set a baseline age-
dependent probability of ‘participants’ attending a visit
each month (Table 3), accounting for the fact that children
are less likely to be taken for routine GP visit as they get
older (in line with evidence that parents find later visits
harder to organise and that there is lower uptake for
booster doses [9, 10]). Stockwell et al. [11] showed in
a US study that a previous bad experience during
vaccination increased the likelihood of later under im-
munisation and Tickner et al. [10] reported a negative
impact of bad experiences on future visits. We
wanted to incorporate scope for these behavioural ef-
fects to impact coverage within the model. We there-
fore estimated the probability of a bad experience for
any single vaccination to be 1 % and assume that a
bad experience reduces the probability of further
visits by 20 % (Table 3). We note that different as-
sumptions around the chance of a bad experience
and the impact on future visits could have been made
for the same overall effective coverage. Our aim was
to choose plausible estimates consistent with observed up-
take data that could be changed should future research
provide better evidence. Finally, primary and booster
courses were treated separately in the model with uptake
switching to that of the booster dose after its completion.
Partial uptake of a primary course was not considered and
we do not allow a missed visit to be completed later
within an extra visit.
Inputs for the modelling framework
Diseases covered and vaccine products available
Within our framework we first identified the set of dis-
eases/causative agents that are either already covered as
part of the UK childhood immunisation programme
Fig. 2 Schematic of the simulation used to estimate vaccine uptake. This shows the logical flow of the simulation model developed to
implement Part I of the framework in this work. The simulation is used to estimate the age-dependent uptake of each vaccine in the immunisa-
tion programme being considered
Table 2 Estimated percentage of parents refusing a vaccine for
each vaccine considered
Vaccines % children whose
parents refuse vaccine
Pediacel (primary and booster); Repevax;
Infanrix Hexa (primary and booster); Infanrix
Penta (primary and booster); Bexsero
0.5 %
Meningitec (primary and booster); Menitorix
(primary and booster); M-M-RVAXPRO (courses 1
and 2); HBVaxPro; Rotarix
1.1 %
Prevenar 13 (courses 1 and 2) 1.5 %
Model inputs for the probability of a participant parent taking their child
for a scheduled GP visit at each age, with and without having a previous
bad experience
Table 3 Model inputs for the probability of attendance
Age (months) Probability of attendance
(no bad experience)
Probability of attendance
(after bad experience)
0-12 98.5 % 79 %
12-24 94.5 % 76 %
24-60 93.5 % 75 %
Model inputs for the probability of a participant parent taking their child
for a scheduled GP visit at each age, with and without having a previous
bad experience
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(Diphtheria, Pertussis, Tetanus, Polio, Neisseria Menin-
gitides Group C, Haemophilus influenzae B, Measles,
Mumps, Rubella, Pneumococcal disease), or that were
considered by DH authors to be possible candidates for
inclusion in the programme within the foreseeable fu-
ture (Hepatitis B and Meningitides Group B). We
note that at the time of conducting the work, the re-
cent decision to introduce Meningitis B vaccination
to the programme had not been made and a procure-
ment contract was agreed (as of end March 2015)
just before submission of this work. Hepatitis A and
Varicella were not included on the basis that, on
cost-effectiveness grounds, they were less likely to be
included in the schedule in the medium term. We
compiled a list of available vaccine products relevant
to these diseases [19–21].
The current immunisation schedule (GP visits)
At the time of writing (August 2015), the current child-
hood immunisation programme in the UK comprises five
scheduled General Practitioner (GP) visits, at 2, 3, 4, 12–13
months and 40–60 months old with immunisation against
11 diseases (see Table 1).
Establishing plausible alternative immunisation schedules
(GP visits)
Assuming it nonviable to withdraw vaccination against
any disease currently targeted, we firstly manually ex-
plored alternative schedules for delivering vaccination
against the diseases targeted by the current programme.
We then extended this by allowing the possible addition
of vaccination against Hepatitis B, Meningitis B, or both
Hepatitis B and Meningitis B. In each case we con-
structed feasible vaccine schedules and attendant prod-
uct combinations under five simplifying assumptions.
Firstly, we assumed that additional vaccinations in the
programme would, where possible, fit into existing
scheduled GP visits, which would remain in the sched-
uled visits of the current programme (unless removed
entirely), and where this was not possible we minimised
the number of additional visits. Secondly, we assumed
that no more than 3 injections would be given in any
one GP visit within infancy (up to 1 year of age) but that
after 1 year, a child can receive 4 injections in any one
visit [DH, private communication]. We note that the
Joint Committee on Vaccination and Immunisation
(JCVI) have recommended the introduction of the Men
B vaccine at months 2, 4 and 12 [22, 23], which would
require four injections in the visit at month 12, so we
explicitly allow for this option. Thirdly, we assumed that
a disease cannot be vaccinated against more than once
within the same visit (i.e. a disease can only be vacci-
nated by one product at any one time). Fourthly, we
ignored vaccination against diseases not explicitly
included in the programme (e.g. as a by-product of a
combination vaccine). Finally, if two or more vaccine
products provide protection against the same diseases
under the same schedule then they were considered
within the same option. We used the Electronic Medi-
cines Compendium [20] to determine possible vaccine
schedules where needed.
Vaccine efficacies
The efficacies of all the relevant vaccine products are
given in Table 4, although we note that the user is able
to adjust these inputs in the implementation of our
simulation. This information originates from three main
sources: the website for The European Medicines
Agency (EMA) [19], the Electronic Medicines Compen-
dium (EMC) [20], and the 2011 Green Book [21]. The
sources reporting the efficacies were not in a consistent
format and were given for different time points during
the vaccination schedule. We used the efficacy corre-
sponding to the percentage of children protected for
lowest effective antibody effect as soon as possible
following the final dose of the primary course of the
vaccine. If a range of efficacies were given or different
efficacies given for different disease serotypes, we used
the average efficacy. The recommended dosing schedule
and known interactions of the vaccine products with
other vaccines were considered and we note that there
are no significant interactions between any vaccines
using our plausible immunisation schedules. Within the
model, we assume this to be the efficacy at the point of
completing the vaccination course (with no efficacy
before completion) and that this efficacy does not wane
over the time period considered (5 years). For diseases
that require a booster, the primary vaccine efficacy is
replaced with the efficacy of the booster once it has been
administered. Some additional vaccine-dependent
assumptions were also incorporated in the model (see
footnotes in Table 4).
Application of the framework to different vaccine scenarios
To demonstrate how the framework could be used, we
applied it to the current UK childhood vaccination
schedule and each of the plausible schedules that had
been established in order to compare the vectors of
effective coverage. We then developed some illustrative
examples, each involving the introduction of Hep B
vaccination, to demonstrate how the programme-view of
vaccine procurement could potentially lead to different
decisions than the case-by-case approach. In Example 1,
we introduce vaccination against Hep B to the current
schedule using HBVaxPro, resulting in an extra GP visit
at 10 months. In Example 2 , vaccination against Hep B
is introduced to the current schedule by replacing the
DtaP primary course (Pediacel) and booster (Repevax or
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Infanrix IPV) with Infranix Hexa and switching the Men
C booster from Menitorix to NeisVac (or Menjugate Kit).
In Example 3 we used the framework to examine a ‘what-
if ’ scenario of interest to policy makers around the pos-
sible impact of a negative media reporting that might im-
pact on parents’ willingness to partake in aspects of the
programme. This is a scenario of particular interest
following the impact of the MMR scare in the UK, which
reduced the coverage for MMR vaccines from 92 % in
1996 to 80 % in 2003 [24, 25]. This Hep B scenario is also
relevant given the public concern and relatively low up-
take of the flu vaccine in the UK [24] and reported paren-
tal concern and low uptake of the Hepatitis B vaccine in
France [26, 27]. In this hypothetical scenario, we assumed
that there was negative media reporting surrounding the
introduction of the Infanrix Hexa vaccine for Hepatitis B
that increased parental refusal of this vaccine (see for in-
stance these 2009 UK media articles worrying about such
an introduction [28, 29]). To model this, we use Op-
tion 5 (Table 6) but assume a higher proportion (5 %
rather than 0.5 %) of parents refusing to attend for
visits where Infanrix Hexa is administered. In addition
to its impact on the coverage of all diseases targeted
by the combination vaccine this would also affect the
Men C, Rotavirus, Pneumococcal and MMR vaccina-
tions. Our intention was to illustrate how strategies
for targeting efforts to improve the vaccination programme
could be informed by scenario analysis such as this, along-
side considerations of feasibility and cost.
Results
Current and plausible future vaccination schedules
When exploring scheduling options for vaccinating
against the 11 diseases that are currently covered by the
immunisation programme in the UK (August 2015), we
found only one alternative combination of vaccines to
the current set that did not violate our constraints. This
alternative involves an earlier booster vaccination for
Diphtheria, Tetanus, Polio, and Pertussis that includes a
(later) booster for Hib, switching to a single vaccine
booster for Men C and an earlier MMR booster (see
Table 5 in comparison with Table 1).
We also found that relatively few additional options
become available with the introduction of further
Table 4 Vaccines considered, the diseases they vaccinate against and the efficacies used in the modelling
Vaccine Diseases vaccinated (efficacy used for modelling) Source
Menjugate or NeisVac Primary (<1 year old) Men C (0.994) EMC
Menjugate or NeisVac Booster (>1 year old) Men C (1) EMC
Menitorix Primary (<1 year old) Men C (0.993), Hib (1) EMC
Menitorix Booster (>1 year old) Men C (0.98 different primary, 1 otherwise), Hib (1) EMC
MMR VAXPRO/Priorix after one dose (>1 year old) Measles (0.90), Mumps (0.64), Rubella (0.99) Green Book
MMR VAXPRO/Prioirix after two dosesa (>1 year old) Measles (0.99), Mumps (0.87), Rubella (0.999) Green Book
Pediacel (<1 year old) Tetanus (1), Polio (1), Diphtheria (0.992), Pertussis (0.987),
Hib (0.91)
EMC
Pediacel (>1 year old) Tetanus (1), Polio (1), Diphtheria (0.991), Pertussis (0.967),
Hib (0.991)
EMC
Prevenar 13 (both doses) Pneumococcal (0.948) EMC
Repevax or Infanrix IPV (>3 years old) Tetanus (1), Polio (1), Diphtheria (1), Pertussis (0.995) EMC
Rotarix (<1 year old) Rotavirus (0.918) EMC
HBVaxPRO (both doses) Hep B (0.96) EMC
Infanrix Hexa (<1 year old) Tetanus (1), Polio (1), Diphtheria (1), Pertussis (1),
Hib (0.964), Hep B (0.995)
European medicines agency
Infanrix Hexa (>1 year old) Tetanus (0.999), Polio (0.999), Diphtheria (0.999),
Pertussis (0.999), Hib (0.997), Hep B (0.984)
European medicines agency
Bexserob Men B (0.836) EMC
aEfficacy after two doses takes into account greater likelihood of successful immune response after two doses. bEfficacy for Bexsero is calculated as the product of
the efficacy against the strains covered (0.95) and the proportion of Men B strains covered (0.88)
Vaccine-dependent modelling assumptions:
For the conjugate vaccines (PCV, Men B and Men C), a child who received only the booster at 12 months is assumed to be fully covered
For the DTaP/Hib vaccines, a child needs to have received both a primary course and a booster dose to be fully covered after the booster dose within the model
(the primary course needs to be fully completed for the booster vaccination to offer protection)
For the MMR vaccine, a single dose is assumed to provide immunity but 10 % of children (randomly selected) don’t respond. A second dose gives these children
another opportunity to be covered: this is not a booster as such, but a way of reducing the proportion of children who don’t respond. Within the model, we estimated
the effective coverage for measles, mumps and rubella according to the number of children in the cohort who received none, one or two MMR vaccinations
For the Men B and Men C vaccines, efficacy was assumed to be zero after the age of ten (due to waning)
For the pneumococcal vaccine, we assumed efficacy was zero after the age of 15
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vaccines, allowing for explicit evaluation of all options.
Specifically, our analysis shows that only three are plaus-
ible when Hep B is included, two when Men B is included
and only one when both are included. The plausible op-
tions are set out in Table 6 and the scheduling of GP visits
associated with each of these is presented in Additional
file 1. When extending the current programme to include
Hep B and/or Men B some interesting examples of poten-
tial trade-offs arise that are set out in the illustrative exam-
ples in Effective coverage. We also note that saturating a
GP visit with the maximum number of injectable vaccines
reduces flexibility for later adding the immunisation
programme without additional visits. In particular, the
planned introduction of Men B immunisation will fill up
the infant schedule (given the reluctance to administer
more than three injections in a single GP visit during
infancy) such that future additions to this part of the
schedule could be problematic.
Effective coverage
Figure 3 shows the effective coverage over time for
Pertussis and Tetanus, both for the current programme
and Option 2 (the alternative feasible schedule for the
current set of diseases). For pertussis, the effective cover-
age is always lower in schedule Option 2 than in the
current programme because, despite the earlier booster in
option 2 resulting in higher uptake of the booster, the
vaccine efficacy of the Pediacel booster (Option 2) is quite
a bit lower than for Repevax/Infanrix IPV. In contrast, for
tetanus the 5 year effective coverage is higher for Option 2
than for the current schedule due to the earlier booster in-
creasing uptake and the equal efficacy of the vaccine prod-
ucts in both cases. However, note that Option 2 is worse
than the current schedule for the 22 months between the
timings for the boosters for the two options since the pri-
mary course has a higher uptake than either booster and,
within our framework, we assume there is no waning be-
tween the primary course and the booster. Although, if
making decisions on timings, waning would need to be
considered, this illustrates why it could be important to
consider the time dependence of the effective coverage,
particularly if the prevalence of the disease being vacci-
nated against has a strong age dependence.
Figures 4 and 5 show the estimated effective coverage
vector at 5 years relative to the current programme for
Options 2–8 and the three illustrative examples respect-
ively. From Fig. 4, we can see that both Option 7 (adding
Men B as a single vaccine) and Option 8 (adding Hep B
as a single vaccine) reduce the effective coverage of
pertussis and Hib because they increase the chances of a
bad experience and the possibility of non-attendance,
thereby reducing coverage. The benefits gained from
vaccinating against either disease would thus need to be
weighed against this loss of coverage elsewhere.
From Fig. 5 we see that introducing Hep B by replacing
the DtaP/IPV/Hib primary course and booster with Infra-
nix Hexa and switching the Men C booster (Example 2)
has benefits over and above the impact of Hep B by
Table 5 A plausible alternative vaccination schedule for the current UK childhood immunisation programme
An alternative to the current UK childhood vaccination schedule by age of the child, showing the diseases covered and the vaccines that can be used (brand
names given). aNote that the introduction of Meningococcal serogroup B (Men B) has been agreed but has not yet started
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improving Pertussis, Hib, Men C protection (higher effi-
cacy for all three), as well as MMR protection (higher
coverage). This is a marked contrast to the generally worse
effective coverage seen across the programme from
Example 1 (Option 7, discussed above). Finally, through
Example 3, where we compare the impact of introducing
a combination vaccine to the current schedule with and
without a vaccine scare, Fig. 5 illustrates how the potential
benefits of introducing a new vaccine are susceptible to
behaviour changes that affect uptake and so its introduc-
tion could potentially result in an overall worsening of the
programme instead of an improvement.
Discussion
We have developed a novel framework for estimating
the effective coverage that would be achieved against
Table 6 Vaccination options for the current UK childhood immunisation programme and plausible extensions to it in the foreseeable future
Diseases targeted Option number Vaccine products Number of visits
Current programme: Diphtheria, Pertussis, Tetanus,
Polio, Neisseria Men C, Hib, Pneumococcal disease,
Measles, Mumps, Rubella and Rotavirus
Option 1 Pediacel; Repevax (or Infanrix IPV); NeisVac (or Menjugate Kit);
Menitorix; Prevenar 13; MMR-VAXPRO (or Priorix); Rotarix
5
Option 2 Pediacel; NeisVac (or Menjugate Kit); Prevenar 13;
MMR-VAXPRO (or Priorix); Rotarix
5
As in current programme + Hepatitis B Option 3 Pediacel; Repevax (or Infanrix IPV); NeisVac (or Menjugate Kit);
Menitorix; Prevenar 13; MMR-VAXPRO (or Priorix); Rotarix;
HBVaxPro
6
Option 4 Pediacel; NeisVac (or Menjugate Kit); Prevenar 13;
MMR-VAXPRO (or Priorix); Rotarix; HBVaxPro
6
Option 5 Infanrix Hexa; NeisVac (or Menjugate Kit); Prevenar 13;
MMR-VAXPRO (or Priorix); Rotarix
5
As in current programme +Men B Option 6 Pediacel; Repevax (or Infanrix IPV); NeisVac (or Menjugate Kit);
Menitorix; Prevenar 13; MMR-VAXPRO (or Priorix); Rotarix;
Bexsero
5
Option 7 Pediacel; NeisVac (or Menjugate Kit); Prevenar 13;
MMR-VAXPRO (or Priorix); Rotarix; Bexsero
5
As in current programme + Hepatitis B + Men B Option 8 Infanrix Hexa; NeisVac (or Menjugate Kit); Prevenar 13;
MMR-VAXPRO (or Priorix); Rotarix; Bexsero
5
Four scenarios were considered: the current immunisation programme; adding Hepatitis B vaccination to the current programme; adding Meningitis B vaccination to
the current programme; and adding both Hepatitis B and Meningitis B vaccination to the current programme. For each scenario we present the feasible combinations
of vaccine products that could target the vaccine preventable diseases, each of which represents a plausible schedule option. Overall this gives rise to the eight possible
options listed: the vaccination schedules for each of these options are contained in Additional file 1
Fig. 3 Estimated age-dependent effective coverage for Tetanus and Pertussis. The effective coverage of population aged 0 to 60 months for
Tetanus and Pertussis estimated using the framework, given the current immunisation programme (solid lines) and Option 2 (an alternative
programme for currently covered diseases, dashed lines)
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each disease included in a given childhood immunisation
schedule and applied this within the context of the UK
vaccination programme.
Firstly, we showed in our analysis that, under certain
assumed constraints, there is only one plausible alternative
vaccine schedule to the current one, an interesting finding
that had not been explicitly recognised by colleagues at
DH prior to this work.
Secondly, when we applied the framework to plausible
extensions of the current (August 2015) immunisation
schedule in the foreseeable future (introducing vaccin-
ation against Men B and/or Hep B) and an additional
-3%
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-1%
0%
1%
2%
3%
Schedule option 2 Schedule option 3
Schedule option 4 Schedule option 5
Schedule option 6 Schedule option 7
Schedule option 8
Disease (effective coverage in current programme)
 
Effective coverage at 5 yrs 
relative to current programme 
Fig. 4 Relative effective coverage vector for Options 2–8. The framework was used to estimate the age-dependent effective coverage against
each of the diseases within a given schedule. We present here the effective coverage against each disease at 5 years for Options 2–8, relative to
the current vaccination regime. We have included the effective coverage under the current vaccination programme in the labels of the diseases
-5%
-4%
-3%
-2%
-1%
0%
1%
2%
3%
4%
5%
Example 1: Introduce single Hep B
vaccine
Example 2: Introduce combination
Hep B vaccine
Example 3: Introduce combination
Hep B vaccine under a vaccine scare
Disease (effective coverage in current programme)
 
Effective coverage at 5 yrs 
relative to current programme 
Fig. 5 Relative effective coverage vector for illustrative examples. The effective coverage against each disease at 5 years relative to the current
vaccination regime is shown for Examples 1–3. We have included the effective coverage under the current vaccination programme in the labels
of the diseases
Crowe et al. BMC Infectious Diseases  (2015) 15:585 Page 9 of 12
scenario exploring the impact of negative media coverage
of a new vaccine, we illustrated how it might be useful to
evaluate the programme-wide impact of a particular
change to an immunisation schedule in contrast to the
case-by-case approach used at present. For instance, intro-
ducing a single Hepatitis B vaccination is shown in one of
our examples (Example 1) to impact negatively on many
parts of the existing programme because it reduces the
overall uptake of vaccines featuring later in the schedule
(by increasing visit fatigue and the chances of a bad
experience), but introducing Hep B as part of a com-
bination vaccination benefits the rest of the programme
since the combination vaccine also has higher efficacy
against already covered diseases. Interestingly, however,
negative media coverage surrounding the introduction of
Hepatitis B, could potentially result in an overall
worsening of the programme benefit of introducing
Hepatitis B to the current schedule even in the most
beneficial schedule option (Example 3). In this illustrative
example, a higher than normal proportion of parents
refuse to attend for visits where the Infanrix Hexa vaccine
is administered, which affects the uptake of the Meningitis
C, Rotavirus, Pneumococcal and MMR vaccinations as
well as Hepatitis B and the other diseases covered by the
combination vaccine, with knock-on negative impact on
programme benefit as a whole.
Within the context of the enormous progress over the
last 60 years in protecting children against diseases such
as Polio and Diphtheria, which are now virtually elimi-
nated in the UK, the current immunisation programme
arguably has greatest room for improvement in better
protecting against: Pertussis (due to the high incidence
[21] and relatively low efficacy of primary vaccine);
Pneumococcal (for which there are many complications
and some long term sequelae [30]) and; Rotavirus (which
affects a lot of small children [2, 31]). Of the plausible
extensions to the current programme, the introduction
of Meningitis B vaccine may be particularly beneficial
since it is serious disease that kills 1 in 10 people af-
fected and leaves a further third with long lasting effects,
some as serious as amputations, brain damage and hear-
ing loss [1, 32]. Indeed, since conducting this work, the de-
cision has been made to introduce Meningitis B
vaccination into the childhood immunisation programme
[23] and, as of March 2015, the UK government have nego-
tiated a procurement contract to enable vaccination to start
later in 2015 or early in 2016 [33] (its routine use is not yet
included in the Meningococcal chapter of the Govern-
ment’s Green Book [34]). This decision was based largely
on considerations of its cost effectiveness and uncertainty
around estimates of cost-effectiveness [22]. Within this
context, our work provides a timely illustration of why it
might also be useful to take a programme-view that con-
siders the potential benefits and scheduling needs of all
vaccinations on the horizon of interest rather than those of
an individual vaccine in isolation. For instance, introducing
Meningitis B immunisation into the current vaccination
schedule would require an additional injection in the early
(2 month) GP visit. Within our framework, this saturates
that 2 month visit with the maximum number of injectable
vaccines, which reduces flexibility for later introductions of
other vaccines to the immunisation programme. For ex-
ample, if immunisation against Hepatitis B was subse-
quently introduced to the programme (in addition to
Meningitis B), this would only be achievable by switching
certain other vaccine products (see schedule Option 8) or
introducing another GP visit to the schedule. On the other
hand, adding both Men B and Hep B to the schedule po-
tentially provides greater overall gain to the immunisation
programme (even excluding any benefit from preventing
Hep B) than adding only Men B because the combination
vaccine that includes Hep B offers better protection for Per-
tussis. This demonstrates how our framework can usefully
augment existing cost-effectiveness analyses and why it
may be important to take a more strategic view of procure-
ment decisions.
This work was conducted in direct response to a
specific request from DH to examine the potential
usefulness of a programme-view in evaluating changes
to the immunisation schedule. Thus one of the strengths
of the work is that we collaborated with the DH to ensure
that our work was informed by the nature of the potential
decisions faced in this area. Aspects of the model develop-
ment, parameterisation and analysis therefore focused on
features of the current UK immunisation programme.
However, we note that our framework is flexible in terms
of input parameters and constraints and can therefore
readily be applied to any vaccination programme and can
easily accommodate possible alterations to incorporate
future vaccination programme changes.
This work has successfully illustrated why it may be
important to take a more strategic view of procurement
decisions. We note, however, that a programme-wide
evaluation of a schedule cannot include the level of
detail incorporated in individual vaccine cost benefit
analyses such as those currently performed when consid-
ering, for example, whether to introduce a particular
vaccine. We therefore stress that this framework is not
proposed as a replacement to cost-effectiveness analyses,
but rather to sit alongside them in informing the difficult
decisions that need to be made regarding vaccine pro-
curement and options for improving the vaccination
programme. We believe that the strategic view demon-
strated using our framework offers a complementary
approach to the current case-by-case one. However,
whilst informative, the effective coverage vector does not
provide an easy means for comparison across different
diseases within a schedule or for the evaluation and
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comparison of different schedules at a programme
level since it does not take into account disease burden
(i.e. weighting the importance of effective coverage by
severity and prevalence of the disease). Thus, the frame-
work presented here represents an important starting
point of what could be a larger-scale definitive framework
able to inform national immunisation policy. For example,
a natural extension of the framework would be to develop
a platform for quantifying disease burden from the vector
of effective coverage by incorporating disease-specific
epidemiological models and, where necessary, developing
models to project the number of disease cases under
different vaccine scenarios.
Conclusions
We have developed a novel framework for estimating
the vector of effective coverage across all of the diseases
in a given vaccination programme and applied it within
the UK context. This is an important step towards pro-
viding decision-makers with a means for systematically
exploring the programme-wide impact of a particular
change to an immunisation schedule and assessing scope
for further reducing the burden of vaccine preventable
disease across a programme. Our analyses using the
framework highlight illustrative circumstances in which
taking such a programme view may be beneficial.
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